We screened previously undiagnosed thrombophilia (V Leiden-prothrombin mutations, Factors VIII and XI, homocysteine, and antiphospholipid antibody [APL] syndrome) in 15 men and 2 women with venous thromboembolism (VTE) or osteonecrosis 7 months (median) after starting testosterone therapy (TT), gel (30-50 mg/d), intramuscular (100-400 mg/wk), or human chorionic gonadotropin (HCG) (6000 IU/wk). Thrombophilia was studied in 2 healthy control groups without thrombosis (97 normal controls, 31 subjects on TT) and in a third control group (n 5 22) with VTE, not on TT. Of the 17 cases, 76% had $1 thrombophilia vs 19% of 97 normal controls (P , 0.0001), vs 29% of 31 TT controls (P 5 0.002). Cases differed from normal controls by Factor V Leiden (12% vs 0%, P 5 0.021), by high Factor VIII (.150%) (24% vs 7%, P 5 0.058), by high homocysteine (29% vs 5%, P 5 0.007), and from both normal and TT controls for APL syndrome (18% vs 2%, P 5 0.023, vs 0%, P 5 0.04). Despite adequate anticoagulation with TT continued after the first deep venous thrombosis-pulmonary embolus (DVT-PE), 1 man sustained 3 DVT-PEs 5, 8, and 11 months later and a second man had 2 DVT-PEs 1 and 2 months later. Of the 10 cases with serum T measured on TT, 6 (60%) had supranormal T (.800 ng/ dL) and of 9 with estradiol measured on TT, 7 (78%) had supranormal levels (.42.6 pg/mL). TT interacts with thrombophilia leading to thrombosis. TT continuation in thrombophilic men is contraindicated because of recurrent thrombi despite anticoagulation. Screening for thrombophilia before starting TT should identify subjects at high risk for VTE with an adverse the risk to benefit ratio for TT. (Translational Research 2015;165:537-548) 
INTRODUCTION
A ndrogen use in men aged $40 has increased more than 3-fold from 0.81% in 2001 to 2.91% in 2011. 1 The broad use of testosterone therapy (TT) may have major public health ramifications, given recent reports of thrombotic [2] [3] [4] [5] [6] [7] and cardiovascular disease (CVD) events [8] [9] [10] associated with TT. Despite lessons learned about venous thromboembolism (VTE) and CVD associated with sex-hormone therapy in postmenopausal women from the Women's Health Initiative, 11, 12 TT is often indiscriminately prescribed to middle-age, obese men without understanding of its long-term risks. 13 Many of these men do not meet highly specific criteria for diagnosis and therapy of hypogonadism.
14 Testosterone (T) levels fall with increasing age, 15, 16 with chronic disease 17, 18 and obesity, 17 and rise with smoking. 19, 20 Part of the problem of increased TT use lies in determination of an age-specific lower normal range for T, because most normal ranges come from healthy younger men. 21 There are also differences in T assay methods 22, 23 and recognition that adverse muscle symptoms occur at different T levels in different subjects. 24 Previously, in aggregate, [2] [3] [4] [5] [6] [7] we have described VTE developing after 5 months (median) in 42 patients on TT, 38 men and 4 women, including 27 with deep venous thrombosis-pulmonary embolism (DVT-PE), 12 with osteonecrosis (ON), 4, 25, 26 1 with central retinal vein occlusion (CRVO), 1 with amaurosis fugax, and 1 with spinal cord infarction. None of the 42 cases in our previous studies [2] [3] [4] [5] [6] [7] had increased hemoglobin or uncontrolled hypertension during TT, which might have contributed to their thrombi. Of the 40 cases having studies of thrombophilia, 39 were found to have previously undiagnosed thrombophiliahypofibrinolysis, including 28% heterozygous for the Factor V (FV) Leiden mutation, 28% with high Factor VIII, and 15% with high Factor XI. 7 In 8 men whose TT was continued, second thrombotic event occurred despite adequate anticoagulation with warfarin. 7 Beyond interacting with familial and acquired thrombophilia, [2] [3] [4] [5] [6] [7] TT is associated with physiological changes that predispose to clotting and thrombosis including hypertension, 27 increased hemoglobin, 28 low highdensity lipoprotein cholesterol, 27, 28 hyperviscosity, and platelet aggregation. [28] [29] [30] Dihydrotestosterone enhances monocyte activation, 31 further promoting acute coronary events. 32 TT also increases circulating estrogens 33 that subsequently play a role in thrombotic events. 7 Oral contraceptives and hormone replacement therapy (HRT) 34, 35 have been identified as risk factors for VTE in women. Given that T is converted by aromatization to estradiol (E2), 36 it may be prothrombotic by the same mechanism as reported in women, where HRT interacts with the FV Leiden mutation to increase risk of VTE. 37 In June 2014, on the basis of postmarketing surveillance reports including our studies, 2-7 both the US Food and Drug Administration (FDA) 38 and Canada Health 39 added a warning regarding the risks of VTE to the label of all T products. VTE, particularly PE, is associated with significant mortality risk. 40 The FDA had previously warned about a TT-associated increase in VTE in men with a diagnosis of increased hemoglobin. 28 However, the June 2014 FDA warning 38 was based on reports of VTE in men without increased hemoglobin.
In the present report, our specific aim was to further focus on thrombotic events in 17 newly reported patients on TT (1 receiving HCG injections as a form of TT 41 ), subsequently found to have previously undiagnosed familial and acquired thrombophilia. Our second specific aim was to assess thrombophilia in our total cohort of 57 patients who sustained VTE on TT, 17 newly reported and 40 previously reported. 7 Our third specific aim was to compare thrombophilia in 57 cases who developed VTE on TT, in 97 healthy normal controls, in 31 men receiving TT without VTE, and in 22 cases with VTE, not taking TT.
MATERIALS AND METHODS
Patients. The procedures followed were in accordance with the ethical standards of the institutional review board of the Jewish Hospital, Cincinnati, Ohio, which approved the research protocol. The protocol was carried out with the understanding, and signed informed consent was taken from each participant.
We excluded patients and controls whose VTE was associated with cancer, polycythemia vera, recent soft AT A GLANCE COMMENTARY Freedman J, et al.
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When testosterone therapy (TT) is given to men and women, thrombotic events occur, reflecting thrombophilic interactions between TT and familial and acquired thrombophilia-hypofibrinolysis.
Translational Significance TT appears to interact with thrombophilia leading to thrombosis. TT continuation in thrombophilic men is contraindicated because of recurrent thrombi despite adequate anticoagulation. Screening for thrombophilia (PCR measures of the Factor V Leiden, and prothrombin gene mutations, Factors VIII and XI, homocysteine, and antiphospholipid antibodies) before starting TT should identify subjects at high risk for venous thromboembolism with an adverse risk/benefit ratio for TT.
tissue trauma, bone fracture, hip-knee-foot surgery, airline flights .8 hours, or extensive immobilization.
Fifteen men and 2 women were studied in their serial order of referral in the last 14 months in our Thrombosis Center by their family physicians-urologists because of thrombotic events. TT had been prescribed by the referring family physicians-urologists, and, if not already stopped, it was discontinued by us before our assessment of thrombophilia and hypofibrinolysis. Measurement of thrombophilia-hypofibrinolysis was carried out at least 2 months after the initial thrombotic event (Figs 1  and 2 ). We focused on 6 thrombophilias previously implicated 7 in a TT-thrombophilia interaction for VTE (FV Leiden 25 and prothrombin gene mutations [PTGs], high Factors VIII and XI, high homocysteine, and the antiphospholipid antibody [APL] syndrome).
The 17 newly acquired cases of the present study were added to 40 previously reported cases 7 to provide 57 cases for comparison with controls ( Figs 3 and 4) .
At study entry, a detailed history [42] [43] [44] for VTE, DVT, PE, recurrent miscarriage, pre-eclampsia, eclampsia, and hemolysis-elevated liver enzymes-low platelet count syndrome was taken for all the cases and their first-degree relatives, along with a history of cigarette smoking.
In the 17 cases and 31 controls receiving TT but without VTE, total serum T and E2 were measured in blood drawn in the morning.
Controls. Six tests for thrombophilia (FV Leiden, PTG, Factors VIII and XI, homocysteine, and APL syndrome) were carried out in 110 healthy controls (46 men and 64 women), free of VTE, not on TT, and in a second control group, 56 healthy subjects (52 men and 4 women) who took T (TT controls), with neither control group having DVT-PE or ON. A third control group included 22 cases referred to us for evaluation of VTE, not taking TT (NTT-VTE controls).
In 31 TT controls and the 22 NTT-VTE controls, at study entry, a detailed history [42] [43] [44] for VTE, DVT, PE, recurrent miscarriage, pre-eclampsia, eclampsia, and hemolysis-elevated liver enzymes-low platelet count syndrome was taken for all probands and their firstdegree relatives, along with a history of cigarette smoking.
In our analysis to optimize comparability of cases and controls, we included cohort of only those cases and controls having complete data for the 6 tests of thrombophilia (FV, PTG, Factors VIII and XI, homocysteine, and APL syndrome), including 97 of the 110 normal controls, 31 of the 56 TT controls, and all 22 of the VTE controls (Table I) .
Laboratory assessment of thrombophilia. Polymerase chain reaction assays. Polymerase chain reaction (PCR) measures of thrombophilia (G1691A FV Leiden and G20210A prothrombin) were performed in all cases and controls using previously published methods 25, 26 by laboratory staff blinded to the participants' status (diagnosis and severity of disease).
Serologic measures of thrombophilia. Serologic measures of thrombophilia included Factors VIII and XI, homocysteine, and the APL syndrome (anticardiolipin antibodies [IgG, IgM] , the lupus anticoagulant, and anti-beta2-glycoprotein). Previously published established methods were used. 25 High homocysteine was identified by levels .the 95th percentile 45 for controls. The 3 components of the APL syndrome were measured by enzyme-linked immunosorbent assay using previously published methods.
46-48
Measures of T and E2. Total T, E2, and free E2 were measured by LabCorp in a single laboratory. Total T and E2 were measured by electrochemiluminescence immunoassay. 49 Statistical methods. All statistical analyses were done using Statistical Analysis System version 9.4. Wilcoxon nonparametric tests were used for comparisons of continuous variables. For categorical variables, Fisher's exact test was used. Analysis of variance was used after covariance adjusting for age to compare homocysteine levels in patients vs normal controls.
RESULTS
Patients and controls. By selection, none of the newly reported 17 cases, the 40 previously reported cases, 7 or the 22 patients with NTT-VTE control group had pathoetiologic causes for DVT-PE (cancer, increased hemoglobin, antecedent trauma or surgery, recent airline travel longer than 8 hours, or extended immobilization).
Because we did not initiate TT in either the TT-treated patients with VTE or the TT controls without VTE, we do not know the etiology of the hypogonadism in the 2 TT-treated groups.
Fifteen men and 2 women were all Caucasian with ages ranging from 23 to 80, mean 54 6 16, median 55 years, 12 of whom were aged #60 (Table II) . None of the patients had sustained thrombotic events before TT.
The 17 cases were older than the 97 normal controls (43 6 12, median 42, P 5 0.006), but their age did not differ from the 31 TT controls (52 6 12, median 52) or from the 22 NTT-VTE controls (59 6 17, median 63), P . 0.05 for both.
Of the 17 cases 6 (35%) had normal body mass index (BMI) (18.5 to ,25 kg/m 2 ), 6 (35%) were overweight (25 to ,30), and 5 (30%) were obese (BMI $ 30) (Table II) . Of the 97 normal controls, 40% had normal BMI, 28% were overweight, and 32% were obese. Of the 31 TT controls, 13% had normal BMI, 48% were overweight, and 39% were obese. Of the 22 VTE controls, 10% had normal BMI, 14% were overweight, and 76% were obese. BMI in the 17 cases did not differ from normal or TT controls (P . 0.2 for both), but the 22 VTE controls were heavier than the 17 cases (median 33.1 vs 27.1 kg/m 2 , P 5 0.01, Wilcoxon). Of the 17 cases, 10 had measures of serum T when on TT, and serum T was supranormal ($800 ng/dL) in 6 (60%) (Table II) , compared with 8 of 29 (28%) TT controls (P 5 0.12). Median T in the cases was higher than in the TT controls (1198 vs 460 ng/dL, P 5 0.018). Of the 17 cases, 9 had measures of E2 when on TT, and of these 9, 7 (78%) had high serum E2 $42.6 pg/mL (Table II) , vs 11 of 28 (39%) TT controls (P 5 0.06). Median E2 in cases differed from TT controls (52.5 vs 35.1 pg/mL, P 5 0.053).
Family history of VTE was positive for 1 of the 17 cases (6%), not different (P . 0.05) from the 31 TT controls (0%) or the 22 VTE controls (10%). Of the 17 cases, 1 smoked (6%), not different (P . 0.05) from 0 of 31 TT controls (0%) or 3 of 22 NTT-VTE controls (14%).
Thrombotic events in cases. Of the 15 men and 2 women, 6 (case IDs 1, 3, 5, 10, 11, and 12, Table II) had DVT alone, 4 (case IDs 2, 6, 8, and 9) had DVT-PE, 1 (case ID 4) had PE alone, 1 (case ID 7) had CRVO and DVT, 2 (case ID14 and 15) had CRVO alone, and 3 (case ID 13, 16, and 17) had ON, In 15 men and 2 women, thrombotic events occurred 7 months (median) after starting TT, with 9 events from 1 to 7 months after starting TT and 8 events from 12 to 36 months (Table II) .
After the initial thrombotic event, TTwas continued in 2 men (case IDs 2 and 9), with concurrent anticoagulation (Table II) . In case ID 2, despite adequate anticoagulation with warfarin (international normalized ratio $ 3.0), DVT-PE occurred a second, third, and fourth time 5, 8, and 11 months after the initial event (Table II) . In case ID 9, after an initial right arm and subclavian thrombus and PE, second and third DVT-PE occurred 1 and 2 months after the initial event, despite full dose Xarelto (20 mg/d) (Table II) .
Thrombophilia. Of the 17 cases, 13 (76%) had $1 thrombophilia vs 19% in 97 normal controls (P , 0.0001), vs 29% in 31 TT controls (P 5 0.002), vs 55% in the 22 VTE controls (P 5 0.2) (Fig 1) . Healthy normal and TT controls did not differ (P 5 0.2) in having $1 thrombophilia 19% vs 29% (Fig 1, Table I ). VTE controls were more likely than healthy normal controls to have $1 thrombophilia 55% vs 19% (P 5 0.002), but did not differ (P 5 0.09) from TT controls 29% (Fig 1, Table I ).
The 17 cases differed from normal controls by FV Leiden (12% vs 0%, P 5 0.021), by high Factor VIII (.150%) (24% vs 7%, P 5 0.058) and by high homocysteine (29% vs 5% P 5 0.007) (Fig 2, Table III ). After covariance adjusting for age, least squares mean mean homocysteine in the 17 cases (11.5 6 0.9 mmol/L) was higher than in the normal controls (8.2 6 0.4), P 5 0.001. The 17 cases differed from both normal and TT controls for the APL syndrome (18% vs 2% in normal controls, P 5 0.023; vs 0% TT controls, P 5 0.039) (Fig 2, Table III ). The 17 cases did not differ (P . 0.05) from the 22 VTE controls for Factor VIII (24% vs 50%), for high homocysteine (29% vs 23%), or for the APL syndrome (18% vs 5%) (Fig 2, Table III) .
Adding coagulation measures from 40 recently published cases 7 to the current 17 cases allowed comparison of 57 patients (53 men, 4 women with VTE on TT) with 97 normal controls, 31 TT controls, and 22 VTE controls. As displayed in Fig 3 and Table IV, 57 cases were much more likely to have $1 of the 6 major thrombophilias (75%) than either normal controls (19%, P , 0.0001) or TT controls (29%, P , 0.0001).
As displayed in Fig 4 and Table IV, 57 cases were much more likely than normal controls to have FV Leiden heterozygosity, high Factor VIII, and high homocysteine, and were also more likely to have V Leiden heterozygosity than the TT controls. VTE controls did not differ significantly from the 57 TT-VTE cases for FV 14% vs 23%, high Factor VIII 50% vs 26% (P 5 0.06), and high homocysteine 23% vs 18% (Fig 4, Table IV) .
Fifty-seven cases with VTE on TT did not differ (P . 0.05) from the 31 TT controls or the 22 VTE controls for a positive family history for VTE 4% vs 0% vs 10%, and did not differ for smoking 11% vs 0% vs 14% (P . 0.05 for all).
Testosterone and estradiol. Of the 57 cases with VTE on TT, 14 had measures of E2 when taking TT (1 taking HCG). E2 or free E2 was high (.42.6, .18 pg/mL) in the 5 cases receiving intramuscular T, and E2 high in 7 of 8 on T gel (P 5 1.0). Of the 57 cases with VTE on TT, 16 had measures of serum T when taking TT, 10 on T gel, and 5 on intramuscular T, and 1 on HCG. Serum T was high (.800 ng/dL) in 5 of 5 cases on intramuscular T and 2 of 10 cases on T gel, Fisher's P 5 0.007.
DISCUSSION
As shown in the present report of 15 men and 2 women who sustained thrombotic events on TT and in our previous report, 7 TT appears to interact with thrombophilia leading to thrombosis. Of the 17 cases, 76% had $1 abnormality of the 6 measured thrombophilias, higher than in 97 healthy controls (19%, P , 0.0001) and higher than in 31 TT controls (29%, P 5 0.0024). In the present study, FV Leiden (12%), high Factor VIII (24%), high homocysteine (26%), and the APL syndrome (18%) were more common in the 17 cases who sustained VTE on TT than in healthy normal controls, and cases also were more likely to have the APL syndrome than in TT controls free of thrombotic events (18% vs 0%).
In the elderly, mild reduction of renal function is accompanied by increased serum homocysteine, 50 and of the 5 cases with serum homocysteine .normals' 95th percentile, the second highest levels were in men aged 75 and 80 years, whereas the remaining 3 subjects with hyperhomocysteinemia were 46, 62, and 72 years old. However, after adjusting for age, mean homocysteine in the 17 cases differed from the 97 normal controls (11.5 vs 8.2 mmol/L, P 5 0.001).
Adding the 17 new cases of the present report to those 40 previously reported, 7 the 57 cases were more likely to have $1 thrombophilia than 97 normal controls (75% vs 19%), or 31 TT controls (75% vs 29%). FV Leiden heterozygosity (23%), high Factor VIII (26%), and high homocysteine (18%) were more common in 57 cases than in 97 healthy normal controls (0%, 7%, and 5%). FV Leiden heterozygosity was also more common in the 57 cases than in TT controls (23% vs 3%). We do not believe that the high percentage of our patients with high Factor VIII (26%) in our study was driven by TT, because the percentage of subjects with high Factor VIII in our TT controls (13%) did not differ (P 5 0.46) from that in 97 normal controls not receiving TT (7%). TT has not been reported to raise Factor VIII, 51 and in a study of risk of thrombosis associated with high Factor VIII, 52 TT was not recognized as a cause of high Factor VIII.
Mild-moderate homocysteinemia was much more common in our 57 cases than in the 97 normal controls (18% vs 5%, P 5 0.022). Mild-moderate homocysteinemia in the range of our patients is a recognized risk factor for venous thrombosis 45, [53] [54] [55] and particularly for ocular vascular thrombosis. 56 The percentage of our 57 patients who developed VTE after starting TT with $1 thrombophilia (75%) was higher than in the 97 normal controls (19%) or the 31 TT controls (29%). Moreover, the percentage of our 57 patients with familial and acquired thrombophilia (23% V Leiden heterozygotes, 7% PTG heterozygotes, 26% high Factor VIII, 11% high Factor XI, 18% high homocysteine, and 9% APL syndrome) was comparable with or higher than reported studies of patients with VTE not taking TT. [57] [58] [59] [60] [61] Turan et al 61 observed FV Leiden heterozygosity in 19% of patients with PE. In a study of 3005 patients with VTE, Gadelha et al 57 reported that 345 (11.4%) had the FV Leiden mutation and 8.7% had the PTG. Ivanov et al 58 reported that the V Leiden mutation was present in 23.5% of patients with PE and the PTG in 5.9%. In 44 patients with DVT, Caprini et al 59 found 23% with the V Leiden mutation. In 318 patients with DVT, Ben Salah et al 60 reported that 22.6% had hereditary thrombophilia and 19.1% had the APL syndrome.
We speculate that TT is likely to result in VTE among men or women 3 with underlying familial or acquired thrombophilia. Similarly, in women on HRT, the presence of the FV Leiden mutation or high Factor VIII increases the risk of DVT 17-fold compared with women on HRT without these thrombophilias. 62 Moreover, the time course between starting TT and VTE, 5 months (median) in our first 42 patients 7 and 7 months (median) in the current 17 patients, is comparable with VTE in women receiving HRT, where VTE rates are highest in the first year of treatment and are much more pronounced in women at higher risk for VTE by virtue of thrombophilia. 35 In our study, family history of VTE was low, being 6% in the 17 cases who developed VTE on TT, 0% in the 31 TT controls, and 10% in the 22 VTE controls. These findings were congruent with previous studies, [42] [43] [44] emphasizing that family history is a weak predictor of VTE. Cigarette smoking (6%) also did not differ between our 17 patients with VTE on TT vs our 31 TT controls (0%) or our 22 VTE controls (14%).
In men, most E2 comes from aromatization of T. 63 We speculate that when exogenous T is aromatized to E2 and E2-associated thrombophilia is superimposed on familial and acquired thrombophilia, as in our present and previous 7 reports, thrombosis occurs. We have previously reported that 45% of men receiving conventional gel TT (50 mg/d) have high serum E2 ($42.6 pg/mL). 4 In the present study, of the 9 men having measures of E2 on TT, 7 (78%) had high E2. The high E2 may also reflect overtreatment with TT. Of the 10 men having measures of T during TT, 6 (60%) had supranormal values (.800 ng/dL), and 5 of these 6 men also had high E2 or free E2. We speculate that in the 17 cases with VTE in the present study, high T and E2 on TT contributed to their VTE, because median T in the 17 cases was higher than in the 31 TT controls (1198 vs 460 ng/dL, P 5 0.018). Median E2 in the 17 cases was higher than in the 31 TT controls (52.5 vs 35.1 pg/mL, P 5 0.053).
After a thrombotic event, if TT is continued, concomitant and adequate anticoagulation does not appear to prevent recurrent thrombotic events. 7 In the present study, when TT was continued along with optimal anticoagulation with warfarin (international normalized ratio $ 3) or (Rivaroxaban 20 mg/d) after an initial thrombotic event, 1 patient sustained 3 subsequent DVT-PEs 5, 8, and 11 months after his first DVT-PE and a second patient had 2 DVT-PEs 1 and 2 months after his first DVT-PE.
There are similar time intervals between starting TT and thrombotic events (median 5 months 7 ) or cardiovascular events (3 months [8] [9] [10] ), and we speculate that the short duration between starting TT and thrombotic and cardiovascular events may indicate a shared thrombotic pathophysiology, because CVD events 3 months after starting TT cannot reflect a conventional arterial atherosclerotic event.
Before starting TT, to facilitate prevention of VTE, we recommend PCR measures of the FV Leiden and PTGs, as well as measures of Factors VIII and XI, homocysteine, and the APL syndrome. In a parallel fashion, the issue of pretreatment thrombophilia screening before giving exogenous estrogens has also been raised in women. 62, [64] [65] [66] Our findings may have important clinical implications, because VTE risk is an important determinant of the benefit to risk ratio of TT. In women, for example, PE accounts for about one third of the incidence of potentially fatal VTE events associated with HRT, 67 and HRT increases the risk of VTE by 2-to 3-fold. 35 We studied only morbid VTE in the present study, a limitation, because mortal VTE might be associated with a larger percentage of subjects with thrombophilia. Because we did not initiate TT in either the TT-treated patients with VTE or TT controls without VTE, we do not know the etiology of the hypogonadism in the 2 TT-treated groups. We had only limited serum T and E2 data in the 57 patients when on TT, with T high in 7 of the 16 cases and E2 high in 12 of 14, and not enough data to determine whether intramuscular T led to higher T and E2 levels than T gel.
An optimal study, paralleling the Women's Health Initiative studies in women 11, 12 would be prospective, placebo-controlled, and double-blind, with thrombotic and CVD end points, and evaluation of increased hemoglobin, hypertension, prostate cancer, and osteoporosis. Alternatively outcomes of TT therapy could be studied retrospectively using administrative health data from health insurance sources provided that laboratory results for thrombophilia measures were consistently coded. This study might allow an examination of an interaction term (TT 3 thrombophilia) revealing, speculatively, that TT is more likely to result in VTE among the subgroup of men with underlying thrombophilia. This study would also allow assessment of whether men with low (,280 ng/dL) or normal serum T levels (280-800 ng/dL) before TT and those who reach supraphysiological levels of T (.800 ng/dL) during TT and those have high E2 on TT (.42.6 pg/mL) are at increased risk for thrombotic and CVD events with or without underlying thrombophilias.
